Na He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Na He has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Ping Liao
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital Guangzhou Medical University Guangzhou China
9 shared publications - Sheng Luo
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
8 shared publications Jie Wang
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, Guangdong, China
6 shared publicationsQiong-Xiang Zhai
Department of Pediatrics, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
6 shared publicationsWang Song
Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, Guangdong, China
6 shared publicationsQian Peng
Department of Pediatrics Dongguan City Maternal and Child Health Hospital, Southern Medical University Dongguan China
5 shared publications
Latest Publications
- 6 July 2026
- Published by Wiley in Epileptic Disorders
Perampanel in Chinese patients with Dravet syndrome: Efficacy and tolerability assessed via a multicenter, prospective, real‐world observational study
Objective: As a third‐generation antiseizure medication, the efficacy of perampanel in treating Dravet syndrome (DS) remains incompletely characterized. This multicenter, prospective, real‐world observational study aimed to evaluate the efficacy and long‐term tolerability of perampanel as adjunctive therapy in Chinese patients with DS. Methods: Patients with unresolved DS were enrolled from four participating hospitals in China between January 2019 and December 2023. All patients received perampanel as add‐on therapy. Efficacy and retention rate were evaluated at 3, 6, and 12 months of perampanel treatment. Genetic screening for SCN1A mutations was performed in all enrolled patients. Results: Fifty‐six patients were enrolled, of whom 48 (85.71%) harbored SCN1A mutations. The mean treatment duration of perampanel was 25.00 ± 7.65 months, with a mean maximum daily perampanel dose of 3.94 ± 1.19 mg. The retention rates at 6 and 12 months were 69.64% and 64.29%, respectively. After 6 and 12 months of treatment, the ≥50% responder rates were 66.07% and 60.71%, while seizure‐freedom rates were 21.43% and 12.50%, respectively. Seizure exacerbation occurred in three patients (5.36%). Adverse events occurred in six patients during treatment (three discontinued treatment), with no new safety concerns identified. Among 30 patients with ≥50% seizure frequency reduction throughout 12‐month treatment who carried SCN1A mutations, 33.33% had truncating mutations, 46.67% had missense mutations, 13.33% had splice site mutations, 3.33% had in‐frame mutations, and 3.33% had large chromosomal deletions encompassing SCN1A . No significant difference in the ≥50% seizure frequency reduction rate was observed between patients with SCN1A truncating mutations and those with missense mutations. Additionally, treatment response to perampanel did not differ significantly according to the specific mutation regions within the Nav1.1 sodium channel. Conclusions: Perampanel demonstrated favorable efficacy and acceptable long‐term tolerability as adjunctive therapy in Chinese patients with DS. The efficacy of perampanel remained consistent regardless of the specific genotype or location of SCN1A mutations.
- 6 July 2026
- Published by Wiley in Epileptic Disorders
Perampanel in Chinese patients with Dravet syndrome: Efficacy and tolerability assessed via a multicenter, prospective, real‐world observational study
Objective: As a third‐generation antiseizure medication, the efficacy of perampanel in treating Dravet syndrome (DS) remains incompletely characterized. This multicenter, prospective, real‐world observational study aimed to evaluate the efficacy and long‐term tolerability of perampanel as adjunctive therapy in Chinese patients with DS. Methods: Patients with unresolved DS were enrolled from four participating hospitals in China between January 2019 and December 2023. All patients received perampanel as add‐on therapy. Efficacy and retention rate were evaluated at 3, 6, and 12 months of perampanel treatment. Genetic screening for SCN1A mutations was performed in all enrolled patients. Results: Fifty‐six patients were enrolled, of whom 48 (85.71%) harbored SCN1A mutations. The mean treatment duration of perampanel was 25.00 ± 7.65 months, with a mean maximum daily perampanel dose of 3.94 ± 1.19 mg. The retention rates at 6 and 12 months were 69.64% and 64.29%, respectively. After 6 and 12 months of treatment, the ≥50% responder rates were 66.07% and 60.71%, while seizure‐freedom rates were 21.43% and 12.50%, respectively. Seizure exacerbation occurred in three patients (5.36%). Adverse events occurred in six patients during treatment (three discontinued treatment), with no new safety concerns identified. Among 30 patients with ≥50% seizure frequency reduction throughout 12‐month treatment who carried SCN1A mutations, 33.33% had truncating mutations, 46.67% had missense mutations, 13.33% had splice site mutations, 3.33% had in‐frame mutations, and 3.33% had large chromosomal deletions encompassing SCN1A . No significant difference in the ≥50% seizure frequency reduction rate was observed between patients with SCN1A truncating mutations and those with missense mutations. Additionally, treatment response to perampanel did not differ significantly according to the specific mutation regions within the Nav1.1 sodium channel. Conclusions: Perampanel demonstrated favorable efficacy and acceptable long‐term tolerability as adjunctive therapy in Chinese patients with DS. The efficacy of perampanel remained consistent regardless of the specific genotype or location of SCN1A mutations.
De novo SRCAP variants cause developmental and epileptic encephalopathy and the phenotypic spectrum
Objective: The SRCAP gene encodes a core catalytic subunit of adenosine triphosphate‐dependent chromatin remodeling complexes that play an essential role in chromatin regulation and neurodevelopment. Our recent study showed that the EP400 gene, the paralog of SRCAP , is associated with neurodevelopmental disorders and epilepsy. This study aims to explore the relationship between SRCAP and developmental and epileptic encephalopathy (DEE) and the phenotypic spectrum of SRCAP variants. Methods: Trio‐based whole‐exome sequencing was performed on patients with DEE from the China Epilepsy Gene 1.0 Project Cohort. Additional cases were screened from other subcohorts. The gene–disease association was validated by minor allele frequency (MAF), damaging effect of variants, genotype–phenotype correlation, and studies on spatial–temporal and single‐cell expression. Results: De novo heterozygous SRCAP variants were identified in five patients with DEE. These variants were truncations or missense variants of severe damage characterized by significant changes in hydrophobicity and protein stability/hydrogen bonding. Additional SRCAP variants were identified in six patients with focal epilepsy (FE), including refractory FE. These variants were characterized by biallelic variants of mild damage, such as in‐frame indel or missense with fewer changes in hydrophobicity and protein stability/hydrogen bonding, which were correlated with the severity of phenotype and outcomes. The epilepsy‐associated variants presented statistically lower MAF than benign variants, with the lowest MAF in DEE‐associated variants. Compared to EP400 , SRCAP presented higher expression in the brain throughout the lifespan. In the late developmental brain, EP400 is predominantly expressed in excitatory neurons, in contrast to the higher proportion of SRCAP expression in inhibitory neurons, explaining the association of SRCAP variants with DEE and refractory FE. Significance: SRCAP is associated with epilepsy and DEE. The phenotypic spectrum ranges from DEE/multisystem developmental disorders to FE of varied severity, depending on the damage of variants. The development‐dependent expression pattern of neuron specificity explains the underlying mechanism of epilepsy outcomes.
De novo SRCAP variants cause developmental and epileptic encephalopathy and the phenotypic spectrum
Objective: The SRCAP gene encodes a core catalytic subunit of adenosine triphosphate‐dependent chromatin remodeling complexes that play an essential role in chromatin regulation and neurodevelopment. Our recent study showed that the EP400 gene, the paralog of SRCAP , is associated with neurodevelopmental disorders and epilepsy. This study aims to explore the relationship between SRCAP and developmental and epileptic encephalopathy (DEE) and the phenotypic spectrum of SRCAP variants. Methods: Trio‐based whole‐exome sequencing was performed on patients with DEE from the China Epilepsy Gene 1.0 Project Cohort. Additional cases were screened from other subcohorts. The gene–disease association was validated by minor allele frequency (MAF), damaging effect of variants, genotype–phenotype correlation, and studies on spatial–temporal and single‐cell expression. Results: De novo heterozygous SRCAP variants were identified in five patients with DEE. These variants were truncations or missense variants of severe damage characterized by significant changes in hydrophobicity and protein stability/hydrogen bonding. Additional SRCAP variants were identified in six patients with focal epilepsy (FE), including refractory FE. These variants were characterized by biallelic variants of mild damage, such as in‐frame indel or missense with fewer changes in hydrophobicity and protein stability/hydrogen bonding, which were correlated with the severity of phenotype and outcomes. The epilepsy‐associated variants presented statistically lower MAF than benign variants, with the lowest MAF in DEE‐associated variants. Compared to EP400 , SRCAP presented higher expression in the brain throughout the lifespan. In the late developmental brain, EP400 is predominantly expressed in excitatory neurons, in contrast to the higher proportion of SRCAP expression in inhibitory neurons, explaining the association of SRCAP variants with DEE and refractory FE. Significance: SRCAP is associated with epilepsy and DEE. The phenotypic spectrum ranges from DEE/multisystem developmental disorders to FE of varied severity, depending on the damage of variants. The development‐dependent expression pattern of neuron specificity explains the underlying mechanism of epilepsy outcomes.
Variants in CSMD2 and CSMD3 , genes involved in synaptogenesis, are associated with epilepsies
Objective: The CSMD genes, including CSMD1 , CSMD2 , and CSMD3 , encoding synaptic transmembrane proteins, play important roles in neuronal maturation, growth of dendrites, and processes of synapses. Our recent study showed that CSMD1 was associated with developmental epileptic encephalopathy (DEE) and generalized epilepsy. The significance of CSMD2 and CSMD3 in human disease is unknown. Methods: Trio‐based whole‐exome sequencing was performed in patients with focal epilepsy without acquired etiologies. The gene–disease association was validated by excess and damaging effect of variants, genotype–phenotype correlation, and studies on spatial–temporal and single‐cell expression. Results: CSMD2 variants were identified in six and CSMD3 variants were identified in four cases with focal epilepsy. Additional CSMD3 variants were identified in three cases with febrile seizures plus and one case with infantile spasms. The variants included 1 de novo , 1 homozygous, and 12 pairs of compound heterozygous variants. All variants were missense except one and presented no or extremely low minor allele frequencies, which were significantly lower than that of benign variants and higher in excess by multiple statistical analyses. The gene–disease association was further supported by correlation between damage scoring of variants and phenotype severity. The three CSMD genes are expressed predominantly at early development stages, correlated with the neurodevelopment abnormalities/DEE. CSMD1 expression increases significantly starting with later childhood, consistent with the poor prognosis of DEE. CSMD2 presented the highest expression in the developing brain, with predominance in inhibitory neurons, explaining the focal epilepsy and focal cortical dysplasia (FCD). CSMD3 expressed in relatively low levels with less neuron‐specificity explained the heterogeneous phenotypes. Significance: The CSMD genes are associated with epilepsies, CSMD2 with focal epilepsy/FCD, and CSMD3 with a phenotype spectrum that includes focal epilepsy, febrile seizures, and DEE. The distinct phenotypes of CSMD genes are explained by their features of genetic dependent stage and the development‐dependent expression pattern of neuron specificity.
Variants in CSMD2 and CSMD3 , genes involved in synaptogenesis, are associated with epilepsies
Objective: The CSMD genes, including CSMD1 , CSMD2 , and CSMD3 , encoding synaptic transmembrane proteins, play important roles in neuronal maturation, growth of dendrites, and processes of synapses. Our recent study showed that CSMD1 was associated with developmental epileptic encephalopathy (DEE) and generalized epilepsy. The significance of CSMD2 and CSMD3 in human disease is unknown. Methods: Trio‐based whole‐exome sequencing was performed in patients with focal epilepsy without acquired etiologies. The gene–disease association was validated by excess and damaging effect of variants, genotype–phenotype correlation, and studies on spatial–temporal and single‐cell expression. Results: CSMD2 variants were identified in six and CSMD3 variants were identified in four cases with focal epilepsy. Additional CSMD3 variants were identified in three cases with febrile seizures plus and one case with infantile spasms. The variants included 1 de novo , 1 homozygous, and 12 pairs of compound heterozygous variants. All variants were missense except one and presented no or extremely low minor allele frequencies, which were significantly lower than that of benign variants and higher in excess by multiple statistical analyses. The gene–disease association was further supported by correlation between damage scoring of variants and phenotype severity. The three CSMD genes are expressed predominantly at early development stages, correlated with the neurodevelopment abnormalities/DEE. CSMD1 expression increases significantly starting with later childhood, consistent with the poor prognosis of DEE. CSMD2 presented the highest expression in the developing brain, with predominance in inhibitory neurons, explaining the focal epilepsy and focal cortical dysplasia (FCD). CSMD3 expressed in relatively low levels with less neuron‐specificity explained the heterogeneous phenotypes. Significance: The CSMD genes are associated with epilepsies, CSMD2 with focal epilepsy/FCD, and CSMD3 with a phenotype spectrum that includes focal epilepsy, febrile seizures, and DEE. The distinct phenotypes of CSMD genes are explained by their features of genetic dependent stage and the development‐dependent expression pattern of neuron specificity.
- Open Access
- 11 May 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (7) , 484-493
Identification of MACF1 as a causative gene of generalised epilepsy
Background: The microtubule actin crosslinking factor 1 (MACF1) gene encodes microtubule–microfilament cross-linking factor 1 that plays an essential role in the embryonic brain development. MACF1 variants were associated with lissencephaly-9 (LIS9). However, the MACF1-epilepsy relationship was unknown. Methods: Trios-based whole-exome sequencing was performed on a cohort with generalised epilepsy from the China Epilepsy Gene 1.0 project. The spatial–temporal expression, single-cell sequencing and genotype–phenotype correlation were analysed to explore the role of MACF1 in epilepsy and neurodevelopment. Results: Two de novo heterozygous and eight biallelic MACF1 variants were identified in 10 unrelated patients. The variants presented significantly high excess by multiple statistical analyses. All patients were diagnosed with generalised epilepsy, among whom three patients presented with neurodevelopmental delay. MACF1 was expressed throughout the lifespan, with three major peaks in the fetal, early childhood and adulthood stages, consistent with seizure onset ages of the patients. The highest expression in adulthood was in the thalamus nucleus, potentially associated with the pathogenesis of generalised epilepsy. The single-cell sequencing in organoids showed MACF1 is widely expressed in the developing brain, especially in the early stage, suggesting a vital role in neurodevelopment. Genotype–phenotype association analysis revealed that LIS9-associated variants were featured by de novo monoallelic variants clustered within the C-terminal; the autism spectrum disorder-associated variants were mainly de novo monoallelic variants located at the spectrin-repeat rod domains. In contrast, the epilepsy-associated variants were biallelic missense variants, and those in the plakin domain were potentially associated with neurodevelopment delay. Significance: MACF1 is potentially a novel causative gene of generalised epilepsy.
- 11 May 2025
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (7) , 484-493
Open AccessIdentification of MACF1 as a causative gene of generalised epilepsy
Background: The microtubule actin crosslinking factor 1 (MACF1) gene encodes microtubule–microfilament cross-linking factor 1 that plays an essential role in the embryonic brain development. MACF1 variants were associated with lissencephaly-9 (LIS9). However, the MACF1-epilepsy relationship was unknown. Methods: Trios-based whole-exome sequencing was performed on a cohort with generalised epilepsy from the China Epilepsy Gene 1.0 project. The spatial–temporal expression, single-cell sequencing and genotype–phenotype correlation were analysed to explore the role of MACF1 in epilepsy and neurodevelopment. Results: Two de novo heterozygous and eight biallelic MACF1 variants were identified in 10 unrelated patients. The variants presented significantly high excess by multiple statistical analyses. All patients were diagnosed with generalised epilepsy, among whom three patients presented with neurodevelopmental delay. MACF1 was expressed throughout the lifespan, with three major peaks in the fetal, early childhood and adulthood stages, consistent with seizure onset ages of the patients. The highest expression in adulthood was in the thalamus nucleus, potentially associated with the pathogenesis of generalised epilepsy. The single-cell sequencing in organoids showed MACF1 is widely expressed in the developing brain, especially in the early stage, suggesting a vital role in neurodevelopment. Genotype–phenotype association analysis revealed that LIS9-associated variants were featured by de novo monoallelic variants clustered within the C-terminal; the autism spectrum disorder-associated variants were mainly de novo monoallelic variants located at the spectrin-repeat rod domains. In contrast, the epilepsy-associated variants were biallelic missense variants, and those in the plakin domain were potentially associated with neurodevelopment delay. Significance: MACF1 is potentially a novel causative gene of generalised epilepsy.
- Open Access
- 11 November 2024
- Published by Springer Nature in Acta Epileptologica
- Vol. 6 (1) , 1-9
Characteristic spatial and frequency distribution of mutations in SCN1A
Background: SCN1A is the most well-recognized and commonly mutated gene related to epilepsy. This study analyzed the characteristic spatial and frequency distributions of SCN1A mutations, aiming to provide important insight into the mutagenesis etiopathology of SCN1A-associated epilepsy. Methods: Epilepsy-associated SCN1A variants were retrieved from the SCN1A mutation database, the HGMD database, and literature reviews. The base substitutions, mutation frequencies in CpG dinucleotides, and spatial distributions of mutations in terms of exons and structural domains were analyzed. Results: A total of 2621 SCN1A variants were identified in 5106 unrelated cases. The most common type was missense mutation, followed by frameshift mutations and splice site mutations. Among the missense mutations, transitions within CpG dinucleotides were much more recurrently identified than transitions within non-CpG dinucleotides, and the most common type was the G > A transition. Among the nonsense mutations, the most predominant type of single-base substitution was the C > T transition, among which 75.3% (235/312) were within CpG sites. The most common “hotspot” codons for missense mutations were codons 101, 946, and 1783; while for nonsense mutations it was codon 712. One-base deletion or insertion was the most common type of frameshift mutation, causing protein truncation. The three most common frameshift mutations were c.5536_5539delAAAC, c.4554dupA, and c.5010_5013delGTTT. Splice mutations were the most frequently identified in exon 4 with a hotspot site c.602 + 1G > A. The spatial distribution of missense mutations showed that exons 22 and 4 had the highest mutation density (111 and 84 mutations per 100 bp, respectively), and exon 12 had the lowest mutation density, with 4 mutations per 100 bp. Further distribution analysis of the protein domains revealed that missense mutations were more common in the pore region and voltage sensor (231 mutations per 100 amino acids, respectively), and the protein truncation mutations were distributed evenly among the domains. Conclusions: SCN1A mutations tend to cluster at distinct sites, depending on the characteristic CpG dinucleotides, exons, and functional domains. Higher mutation density in particular regions, such as exon 22 and exon 4, offers promising targets for therapeutic genetic interventions.
- 11 November 2024
- Published by Springer Nature in Acta Epileptologica
- Vol. 6 (1) , 1-9
Open AccessCharacteristic spatial and frequency distribution of mutations in SCN1A
Background: SCN1A is the most well-recognized and commonly mutated gene related to epilepsy. This study analyzed the characteristic spatial and frequency distributions of SCN1A mutations, aiming to provide important insight into the mutagenesis etiopathology of SCN1A-associated epilepsy. Methods: Epilepsy-associated SCN1A variants were retrieved from the SCN1A mutation database, the HGMD database, and literature reviews. The base substitutions, mutation frequencies in CpG dinucleotides, and spatial distributions of mutations in terms of exons and structural domains were analyzed. Results: A total of 2621 SCN1A variants were identified in 5106 unrelated cases. The most common type was missense mutation, followed by frameshift mutations and splice site mutations. Among the missense mutations, transitions within CpG dinucleotides were much more recurrently identified than transitions within non-CpG dinucleotides, and the most common type was the G > A transition. Among the nonsense mutations, the most predominant type of single-base substitution was the C > T transition, among which 75.3% (235/312) were within CpG sites. The most common “hotspot” codons for missense mutations were codons 101, 946, and 1783; while for nonsense mutations it was codon 712. One-base deletion or insertion was the most common type of frameshift mutation, causing protein truncation. The three most common frameshift mutations were c.5536_5539delAAAC, c.4554dupA, and c.5010_5013delGTTT. Splice mutations were the most frequently identified in exon 4 with a hotspot site c.602 + 1G > A. The spatial distribution of missense mutations showed that exons 22 and 4 had the highest mutation density (111 and 84 mutations per 100 bp, respectively), and exon 12 had the lowest mutation density, with 4 mutations per 100 bp. Further distribution analysis of the protein domains revealed that missense mutations were more common in the pore region and voltage sensor (231 mutations per 100 amino acids, respectively), and the protein truncation mutations were distributed evenly among the domains. Conclusions: SCN1A mutations tend to cluster at distinct sites, depending on the characteristic CpG dinucleotides, exons, and functional domains. Higher mutation density in particular regions, such as exon 22 and exon 4, offers promising targets for therapeutic genetic interventions.
- Open Access
- 4 July 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (9) , 895-903
IFIH1 variants are associated with generalised epilepsy preceded by febrile seizures
Background: IFIH1 variants have been reported to be associated with immune-related disorders with/without seizures. It is unknown whether IFIH1 variants are associated with common epilepsy without acquired causes and the mechanism underlying phenotypic variation remains elusive. Methods: Trio-based whole-exome sequencing was performed on patients with febrile seizures or epilepsy with antecedent febrile seizures. Previously reported variants were systematically reviewed to investigate genotype-phenotype associations. Results: Two de novo heterozygous and three biallelic missense variants were identified in five patients with generalised epilepsy with antecedent febrile seizures. The variants were predicted to be damaging by in silico tools and were associated with hydrogen bonding changes to neighbouring amino acids or decreased protein stability. Patients exhibited an early onset age and became seizure-free with favourable outcome. Further analysis revealed that de novo missense variants located in the Hel region resulted in seizures with multiple neurological abnormalities, while those in the pincer domain or C-terminal domain led to seizures with normal neurodevelopment, suggesting a sub-molecular effect. Biallelic missense variants, which were inherited from unaffected parents and presented low allele frequencies in general populations, were associated with seizures without neurological abnormalities. Truncation variants were related to refractory epilepsy and severe developmental delay, suggesting a genotype-phenotype correlation. IFIH1 is predominantly expressed in the neonatal stage and decreases dramatically in the adulthood, which is consistent with the early onset age and favourable outcome of the patients. Conclusions: IFIH1 variants are potentially associated with generalised epilepsy with antecedent febrile seizures. The sub-molecular implication and genotype-phenotype association help explain phenotype variations of IFIH1 variants.
- 4 July 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (9) , 895-903
Open AccessIFIH1 variants are associated with generalised epilepsy preceded by febrile seizures
Background: IFIH1 variants have been reported to be associated with immune-related disorders with/without seizures. It is unknown whether IFIH1 variants are associated with common epilepsy without acquired causes and the mechanism underlying phenotypic variation remains elusive. Methods: Trio-based whole-exome sequencing was performed on patients with febrile seizures or epilepsy with antecedent febrile seizures. Previously reported variants were systematically reviewed to investigate genotype-phenotype associations. Results: Two de novo heterozygous and three biallelic missense variants were identified in five patients with generalised epilepsy with antecedent febrile seizures. The variants were predicted to be damaging by in silico tools and were associated with hydrogen bonding changes to neighbouring amino acids or decreased protein stability. Patients exhibited an early onset age and became seizure-free with favourable outcome. Further analysis revealed that de novo missense variants located in the Hel region resulted in seizures with multiple neurological abnormalities, while those in the pincer domain or C-terminal domain led to seizures with normal neurodevelopment, suggesting a sub-molecular effect. Biallelic missense variants, which were inherited from unaffected parents and presented low allele frequencies in general populations, were associated with seizures without neurological abnormalities. Truncation variants were related to refractory epilepsy and severe developmental delay, suggesting a genotype-phenotype correlation. IFIH1 is predominantly expressed in the neonatal stage and decreases dramatically in the adulthood, which is consistent with the early onset age and favourable outcome of the patients. Conclusions: IFIH1 variants are potentially associated with generalised epilepsy with antecedent febrile seizures. The sub-molecular implication and genotype-phenotype association help explain phenotype variations of IFIH1 variants.
- 22 March 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 87-92
Reprint of: Recessive APC2 missense variants associated with epilepsies without neurodevelopmental disorders
- 22 March 2024
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 87-92
Reprint of: Recessive APC2 missense variants associated with epilepsies without neurodevelopmental disorders
- Open Access
- 20 March 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (7) , 652-660
ZFHX3 variants cause childhood partial epilepsy and infantile spasms with favourable outcomes
Background: The ZFHX3 gene plays vital roles in embryonic development, cell proliferation, neuronal differentiation and neuronal death. This study aims to explore the relationship between ZFHX3 variants and epilepsy. Methods: Whole-exome sequencing was performed in a cohort of 378 patients with partial (focal) epilepsy. A Drosophila Zfh2 knockdown model was used to validate the association between ZFHX3 and epilepsy. Results: Compound heterozygous ZFHX3 variants were identified in eight unrelated cases. The burden of ZFHX3 variants was significantly higher in the case cohort, shown by multiple/specific statistical analyses. In Zfh2 knockdown flies, the incidence and duration of seizure-like behaviour were significantly greater than those in the controls. The Zfh2 knockdown flies exhibited more firing in excitatory neurons. All patients presented partial seizures. The five patients with variants in the C-terminus/N-terminus presented mild partial epilepsy. The other three patients included one who experienced frequent non-convulsive status epilepticus and two who had early spasms. These three patients had also neurodevelopmental abnormalities and were diagnosed as developmental epileptic encephalopathy (DEE), but achieved seizure-free after antiepileptic-drug treatment without adrenocorticotropic-hormone/steroids. The analyses of temporal expression (genetic dependent stages) indicated that ZFHX3 orthologous were highly expressed in the embryonic stage and decreased dramatically after birth. Conclusion: ZFHX3 is a novel causative gene of childhood partial epilepsy and DEE. The patients of infantile spasms achieved seizure-free after treatment without adrenocorticotropic-hormone/steroids implies a significance of genetic diagnosis in precise treatment. The genetic dependent stage provided an insight into the underlying mechanism of the evolutional course of illness.
- 20 March 2024
- Published by BMJ in Journal of Medical Genetics
- Vol. 61 (7) , 652-660
Open AccessZFHX3 variants cause childhood partial epilepsy and infantile spasms with favourable outcomes
Background: The ZFHX3 gene plays vital roles in embryonic development, cell proliferation, neuronal differentiation and neuronal death. This study aims to explore the relationship between ZFHX3 variants and epilepsy. Methods: Whole-exome sequencing was performed in a cohort of 378 patients with partial (focal) epilepsy. A Drosophila Zfh2 knockdown model was used to validate the association between ZFHX3 and epilepsy. Results: Compound heterozygous ZFHX3 variants were identified in eight unrelated cases. The burden of ZFHX3 variants was significantly higher in the case cohort, shown by multiple/specific statistical analyses. In Zfh2 knockdown flies, the incidence and duration of seizure-like behaviour were significantly greater than those in the controls. The Zfh2 knockdown flies exhibited more firing in excitatory neurons. All patients presented partial seizures. The five patients with variants in the C-terminus/N-terminus presented mild partial epilepsy. The other three patients included one who experienced frequent non-convulsive status epilepticus and two who had early spasms. These three patients had also neurodevelopmental abnormalities and were diagnosed as developmental epileptic encephalopathy (DEE), but achieved seizure-free after antiepileptic-drug treatment without adrenocorticotropic-hormone/steroids. The analyses of temporal expression (genetic dependent stages) indicated that ZFHX3 orthologous were highly expressed in the embryonic stage and decreased dramatically after birth. Conclusion: ZFHX3 is a novel causative gene of childhood partial epilepsy and DEE. The patients of infantile spasms achieved seizure-free after treatment without adrenocorticotropic-hormone/steroids implies a significance of genetic diagnosis in precise treatment. The genetic dependent stage provided an insight into the underlying mechanism of the evolutional course of illness.
- Open Access
- 27 October 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 119-125
DYNC1H1 variants associated with infant-onset epilepsy without neurodevelopmental disorders
- 27 October 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 119-125
Open AccessDYNC1H1 variants associated with infant-onset epilepsy without neurodevelopmental disorders
- Top Cited Papers
- 23 September 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 4-13
Epilepsy-associated genes: an update
- 23 September 2023
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 116, 4-13
Top Cited PapersEpilepsy-associated genes: an update